Bufei huoxue capsules in the management of convalescent COVID‐19 infection: study protocol for a multicenter, double‐blind, and randomized controlled trial-Reference-Cited by-同舟云学术

Bufei huoxue capsules in the management of convalescent COVID‐19 infection: study protocol for a multicenter, double‐blind, and randomized controlled trial

Published:2021-07 Issue:3 Volume:11 Page:1-9
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Chen Yuqin¹,He Wenjun¹^ORCID,Lu Wenju¹,Xing Yue¹,Bai Jianling²,Yu Hao²,Zhou Jiawei²,Liang Jingyi¹,Chen Jiyuan¹,Hou Chi¹³,Zhong Bihua¹,Wang Ting⁴,Feng Huazhuo¹,Chen Xu¹,Wang Tao¹,Yang Kai¹,Zhang Nuofu¹,Zhong Nanshan¹,Liu Chunli¹,Wang Jian¹

Affiliation:

1. State Key Laboratory of Respiratory DiseaseNational Center for Respiratory MedicineNational Clinical Research Center for Respiratory DiseaseGuangdong Key Laboratory of Vascular DiseaseGuangzhou Institute of Respiratory HealthThe First Affiliated Hospital of Guangzhou Medical UniversityGuangzhouChina

2. Department of BiostatisticsSchool of Public HealthNanjing Medical UniversityNanjingChina

3. Department of NeurologyGuangzhou Women and Children’s Medical CenterGuangzhouChina

4. Department of Respiratory Children’s Hospital of Chongqing Medical UniversityNational Clinical Research Center for Child Health and DisordersMinistry of Education Key Laboratory of Child Development and DisordersChongqingChina

Funder

Guangdong Leiyunshang Pharmaceutical Co., Ltd.

Guangzhou Institute of Respiratory Health for Key Research of Independent Project

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/20458940211032125

Reference37 articles.

1. Worldometer. COVID‐19 coronavirus pandemic https://www.worldometers.info/coronavirus/(2021 accessed 30 May2021).

2. The lingering manifestations of COVID‐19 during and after convalescence: update on long‐term pulmonary consequences of coronavirus disease 2019 (COVID‐19;Shaw B;Radiol Med,2020

3. Cardiopulmonary recovery after COVID‐19 – an observational prospective multi‐center trial;Sonnweber T;Eur Respir J

4. Lei Yun Shang Pharmaceutical Group Co. Ltd. The official production introduction of Bufei Huoxue Capsules http://www.lys.cn/productsandintroductions/info.aspx?itemid=55&Lcid=20(2021 accessed 30 May2021).

5. Improving the body's immunity and delaying aging – on the new medicinal uses of Ginkgo biloba, berries, and astragalus.;Li Y;Chin J Pract Tradit Chin West Med,2003

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New insight into the molecular mechanism of TCM Bufei Huoxue formula for chronic obstructive pulmonary disease based on network pharmacology and experimental verification;Journal of Pharmacy and Pharmacology;2024-08-21

2. Bufei huoxue capsule alleviates bleomycin-induced pulmonary fibrosis in mice via TGF-β1/Smad2/3 signaling;Journal of Ethnopharmacology;2023-11

3. Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: A multicentre, double-blind, and randomised controlled trial;Journal of Ethnopharmacology;2022-02